Company Website:
http://www.auriniapharma.com
VICTORIA, British Columbia -- (Business Wire)
Aurinia Pharmaceuticals Inc., (NASDAQ: AUPH / TSX: AUP) announced today
that it has been selected for addition to the NASDAQ Biotechnology Index®
(Nasdaq:^NBI), which will become effective prior to market open on
Monday, December 18, 2017.
The NASDAQ Biotechnology Index is designed to track the performance of a
set of NASDAQ-listed securities that are classified as either
biotechnology or pharmaceutical according to the Industry Classification
Benchmark. The NASDAQ Biotechnology Index is re-ranked annually. The
NASDAQ Biotechnology Index is the basis for the iShares NASDAQ
Biotechnology Index Fund (Nasdaq:IBB), which seeks investment results
that correspond generally to the price and yield performance, before
fees and expenses, of the NASDAQ Biotechnology Index. In addition,
options based on the iShares NASDAQ Biotechnology Index Fund trade on
various exchanges. For more information about the NASDAQ Biotechnology
Index please visit https://indexes.nasdaqomx.com/Index/Overview/NBI.
Additionally, Aurinia was recently added to the MSCI Global Small Cap
Indexes, which went into effect at close of November 30, 2017. Canada
added 17 securities and deleted 7 securities from MSCI Global Small Cap
indexes.
About Aurinia
Aurinia is a clinical stage
biopharmaceutical company focused on developing and commercializing
therapies to treat targeted patient populations that are suffering from
serious diseases with a high unmet medical need. The company is
currently developing voclosporin, an investigational drug, for the
treatment of LN, FSGS, MCD and DES. The company is headquartered in
Victoria, BC and focuses its development efforts globally. For further
information, see our website at www.auriniapharma.com.
We seek safe harbor.
View source version on businesswire.com: http://www.businesswire.com/news/home/20171211006070/en/
Contacts:
Aurinia Pharmaceuticals Inc.
Investor Contact:
Celia
Economides
VP, Corporate & Public Affairs
IR@auriniapharma.com
or
Media:
Christopher
Hippolyte, 212-364-0458
Christopher.hippolyte@inventivhealth.com
Source: Aurinia Pharmaceuticals Inc.
© 2024 Canjex Publishing Ltd. All rights reserved.